BREAKING
Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 9 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 10 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 11 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 23 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 23 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 1 day ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 1 day ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 1 day ago Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 9 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 10 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 11 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 23 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 23 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 1 day ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 1 day ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 1 day ago
ADVERTISEMENT
AlphaGraphs

Walgreens Boots Alliance (WBA) Q3 2025 Earnings: Key financials and quarterly highlights

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) reported its third quarter 2025 earnings results today. Sales increased 7.2% year-over-year to $39 billion. Sales were up 6.9% on a constant currency basis. The top line results reflected sales growth in the US Retail Pharmacy and International segments. Net loss was $175 million, or $0.20 per share, compared to net earnings of $344 million, or $0.40 […]

$WBA June 26, 2025 1 min read

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) reported its third quarter 2025 earnings results today.

Sales increased 7.2% year-over-year to $39 billion. Sales were up 6.9% on a constant currency basis. The top line results reflected sales growth in the US Retail Pharmacy and International segments.

Net loss was $175 million, or $0.20 per share, compared to net earnings of $344 million, or $0.40 per share, last year. Adjusted EPS was $0.38, down 39.6% on a constant currency basis.

US Retail Pharmacy segment sales were $30.7 billion, up 7.8% from the year-ago quarter. 

International segment sales were $6.2 billion, up 7.8% YoY.

ADVERTISEMENT

US Healthcare segment sales were $2.1 billion, slightly down from last year.

Given its pending acquisition by Sycamore Partners, WBA previously withdrew its guidance for fiscal year 2025.

ADVERTISEMENT